$CANFJul 14, 2026, 11:00 AMAI processed
CANF: Australian patent allowance for Namodenoson in liver & pancreatic cancer
AI Summary
Can‐Fite said the Australian Patent Office allowed Patent Application No. 2021290439 covering treatment of advanced metastatic cancer, strengthening intellectual property around its Namodenoson oncology program. Namodenoson is in a pivotal Phase 3 for advanced hepatocellular carcinoma and completed a Phase 2a in pancreatic cancer (with a planned Phase 2b combo with gemcitabine), so the allowance supports commercialization/exclusivity in a key market but does not change clinical status or approvals.
Positives
- Australian Patent Office allowed App. No. 2021290439 covering treatment of advanced metastatic cancer for Namodenoson
- Namodenoson is in a pivotal Phase 3 trial for advanced HCC and has FDA Fast Track plus U.S./EU orphan designations
- Completed Phase 2a in pancreatic cancer with favorable safety and encouraging survival signals and plans a Phase 2b combo study with gemcitabine
Negatives
- Allowance is specific to Australia and does not confer regulatory approval or global market exclusivity
- Therapeutic value and commercial impact still depend on upcoming Phase 3/Phase 2b trial results and regulatory approvals
- Company highlights standard forward‑looking risks including financing and execution risks that could affect development/commercialization